# US 2003/0229040 A1 · Cationic liposomal delivery system and therapeutic use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229040 A1
- Document ID: US20030229040A1
- Status: Published application
- Kind: A1
- Application number: 10/347,924
- Filed: 2003-01-21
- Published: 2003-12-11
- Earliest claimed: 1997-03-21
- Assignees: Georgetown University
- Inventors: Usha Kasid; Prafulla Gokhale; Chuanbo Zhang; Anatoly Dritschilo; Aquilur Rahman
- Web page: https://patentgrep.com/patent/US20030229040A1

## CPC

- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/315: Phosphorothioates
- C12N 2310/345: having at least two different backbone modifications
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The invention relates to novel cationic lipid formulations and use thereof for treatment of cancer, especially in combination with radiation.

## Claims

### Claim 1

A method of radiosensitizing raf oncogene expressing tumor tissue in a subject in need of such treatment comprising administering a radiosensitizing effective amount of a cationic liposomal formulation comprising at least one cationic lipid selected from the group consisting of dimethyldioctadecyl ammonium bromide (DDAB); 1,2-dioleoyl-3-trimethyl ammonium propane (DOTAP), N-(2,3-(dioleoyloxy)propyl)-N,N,N-trimethly ammonium chloride; 1-[2-(9(Z)-octadecenoyloxy)-ethyl]-2-(8(Z) heptadecenyl)-3-(2-hydroxyethyl)-imidazolinium chloride); and 1,2-dimyristoyl-3-trimethyl ammonium propane (DMTAP); and further comprising phosphatidylcholine and cholesterol; and further having encapsulated therein at least one antisense oligonucleotide that is at most 40 bases which specifically binds to a Raf-1 nucleic acid sequence expressed by said tumor tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oligonucleotide ranges in size from 15 to 40 nucleotides.

### Claim 3 (depends on 1)

The method of claim 1, wherein the oligonucleotide ranges in size from 15 to 25 nucleotides.

### Claim 4 (depends on 1)

The method of claim 1, wherein the respective molar amounts of cationic lipid:phosphatidylcholine:cholesterol range from (1.0-2.0):(2.0-4.0):(1.0-2.0).

### Claim 5 (depends on 1)

The method of claim 1, wherein said respective molar amounts are 1.0:3.2:1.6.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cationic lipid is DOTAP.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cationic lipid is DDAB.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cationic lipid is DMTAP.

### Claim 9 (depends on 1)

The method of claim 1, wherein the oligonucleotide is 5′-GTGCTCCATT-GATGC-3′ (SEQ ID NO: 1).

### Claim 10 (depends on 9)

The method of claim 9, wherein said oligonucleotide comprises at least one modified base.
